Anti-inflammation conferred by stimulation of CD200R1 via Dok1 pathway in rat microglia after germinal matrix hemorrhage

J Cereb Blood Flow Metab. 2019 Jan;39(1):97-107. doi: 10.1177/0271678X17725211. Epub 2017 Aug 9.

Abstract

CD200 has been reported to be neuroprotective in neurodegenerative diseases. However, the potential protective effects of CD200 in germinal matrix hemorrhage (GMH) have not been investigated. We examined the anti-inflammatory mechanisms of CD200 after GMH. A total of 167 seven-day-old rat pups were used. The time-dependent effect of GMH on the levels of CD200 and CD200 Receptor 1 (CD200R1) was evaluated by western blot. CD200R1 was localized by immunohistochemistry. The short-term (24 h) and long-term (28 days) outcomes were evaluated after CD200 fusion protein (CD200Fc) treatment by neurobehavioral assessment. CD200 small interfering RNA (siRNA) and downstream of tyrosine kinase 1 (Dok1) siRNA were injected intracerebroventricularly. Western blot was employed to study the mechanisms of CD200 and CD200R1. GMH induced significant developmental delay and caused impairment in both cognitive and motor functions in rat pups. CD200Fc ameliorated GMH-induced damage. CD200Fc increased expression of Dok1 and decreased IL-1beta and TNF-alpha levels. CD200R1 siRNA and Dok1 siRNA abolished the beneficial effects of CD200Fc, as demonstrated by enhanced expression levels of IL-1beta and TNF-alpha. CD200Fc inhibited GMH-induced inflammation and this effect may be mediated by CD200R1/Dok1 pathway. Thus, CD200Fc may serve as a potential treatment to ameliorate brain injury for GMH patients.

Keywords: CD200; CD200Receptor 1; Germinal matrix hemorrhage; downstream of tyrosine kinase 1; microglia.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Animals, Newborn
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / pathology
  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / pathology
  • DNA-Binding Proteins / drug effects*
  • Developmental Disabilities / etiology
  • Immunoglobulin G / therapeutic use
  • Immunohistochemistry
  • Inflammation / pathology*
  • Injections, Intraventricular
  • Interleukin-1beta / antagonists & inhibitors
  • Microglia / drug effects*
  • Phosphoproteins / drug effects*
  • RNA, Small Interfering / administration & dosage
  • RNA, Small Interfering / therapeutic use
  • RNA-Binding Proteins / drug effects*
  • Rats
  • Receptors, Immunologic / agonists*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • CD200-FC, mouse
  • Cd200 protein, rat
  • DNA-Binding Proteins
  • Dok1 protein, rat
  • Immunoglobulin G
  • Interleukin-1beta
  • Phosphoproteins
  • RNA, Small Interfering
  • RNA-Binding Proteins
  • Receptors, Immunologic
  • Tumor Necrosis Factor-alpha